Darwin Global Management, Ltd. Inhibrx, Inc. Transaction History

Darwin Global Management, Ltd.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$19.89 - $43.18 $11.8 Million - $25.6 Million	-591,975 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$26.75 - $46.02 $1.32 Million - $2.27 Million	49,389 Added 9.1%	591,975 $25.9 Million
Q3 2021 Nov 15, 2021	BUY	$25.18 - $37.81 $7.98 Million - $12 Million	317,106 Added 140.64%	542,586 $18.1 Million
Q2 2021 Aug 16, 2021	BUY	$14.69 - $27.52 $2.58 Million - $4.84 Million	175,771 Added 353.6%	225,480 $6.21 Million
Q1 2021 May 17, 2021	BUY	$16.27 - $41.26 $214,357 - $543,600	13,175 Added 36.06%	49,709 $998,000
Q4 2020 Feb 16, 2021	BUY	$15.96 - $50.0 $583,082 - $1.83 Million	36,534 New	36,534 $1.21 Million

25.3K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $626M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Darwin Global Management, Ltd., based on Form 13F filings with the SEC.

Stay updated on Darwin Global Management, Ltd. with notifications on news.